In ONCOMINE, we found that FUNDC1, compared with expression levels in normal tissues, was highly expressed in breast, cervical, colorectal, lung, ovarian, pancreatic, and prostate cancers, as well as in leukemia and lymphoma, while only one dataset showed that FUNDC1 had a lower expression level in breast cancer (Figure 1A). Here, FUNDC1 is linked to prostate carcinoma.